An open-label, multi-centre study to evaluate efficacy and safety of gefitinib as the first-line treatment for locally advanced (IIIB), metastatic (IV) or recurrent pulmonary adenocarcinoma patients with EGFR [epidermal growth factor receptor] mutation
Phase of Trial: Phase II
Latest Information Update: 28 Jun 2010
At a glance
- Drugs Gefitinib (Primary)
- Indications Lung cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 03 Jun 2010 Actual patient number (46) added as reported by ClinicalTrials.gov.
- 05 Oct 2008 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
- 18 Dec 2007 Status changed from recruiting to in progress.